Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Datadog Inc (DDOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Datadog Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Datadog Inc trades at $258.58 (market cap $91.67B). The key difference: Datadog Inc is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Datadog Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DDOG | |
|---|---|---|
Market Cap | $39.89B | $91.67B |
Sector | Health | Technology |
52-Week High | $491.22 | $277.49 |
52-Week Low | $278.09 | $102.62 |
Enterprise Value | $38.15B | $88.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Datadog (DDOG) trades at $257.54, down 4.25% on the day, with strong technical momentum indicators showing bullish moving averages but overbought RSI readings. The company maintains impressive revenue growth, reaching $3.43B in 2025, with consistent earnings beats in recent quarters. Recent acquisition of Adaptive ML positions DDOG for AI-driven growth, though valuation metrics remain elevated with P/E of 660 and P/S of 25.5.
Outlook remains positive with 83% analyst buy ratings and $246 consensus target, though current price exceeds target. Key risks include high valuation multiples, moderating growth guidance, and competitive pressures in cloud observability. The stock's 88.7% YTD surge suggests much optimism is priced in, requiring continued execution to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →
